EYP-1901
AssetSmall molecule
Tyrosine kinase inhibitor formulation delivering sustained-release vorolanib to inhibit VEGFR/PDGFR signaling
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- FLT1
- Indications
- 2
- Trials
- 2
- Developers
- 1
Indications
2Diabetic macular edema
Phase 3ACTIVE_NOT_RECRUITINGNCT07449923clinicaltrials.gov7 Oct 2026
DME
Phase 3ACTIVE_NOT_RECRUITINGNCT07449923clinicaltrials.gov7 Oct 2026
- Targets and what it contains3
- Owner and partners1
- Trials2
- Evidence for its targets2
- Competitors7
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 2 sources